Safety and Tolerability Evaluation of Sintilimab in Combination With Radiation in Stage IV NSCLC Patients
Multi-center Phase I Study of Sintilimab in Combination With Radiotherapy in Treatment Naive PD-L1 Positive Stage IV Non-small Cell Lung Cancer (NSCLC)
Sponsor: Innovent Biologics (Suzhou) Co. Ltd.
Listed as NCT03812549, this PHASE1 trial focuses on Stage IV NSCLC and remains completed. Sponsored by Innovent Biologics (Suzhou) Co. Ltd., it has been updated 8 times since 2019, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
8 versions recorded-
Apr 2025 — Present [monthly]
Completed PHASE1
-
Sep 2024 — Apr 2025 [monthly]
Completed PHASE1
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE1
-
Sep 2022 — Jul 2024 [monthly]
Completed PHASE1
Status: Recruiting → Completed
-
Apr 2021 — Sep 2022 [monthly]
Recruiting PHASE1
▶ Show 3 earlier versions
-
Jan 2021 — Apr 2021 [monthly]
Recruiting PHASE1
-
Dec 2019 — Jan 2021 [monthly]
Recruiting PHASE1
-
Feb 2019 — Dec 2019 [monthly]
Recruiting PHASE1
First recorded
Jan 2019
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Innovent Biologics (Suzhou) Co. Ltd.
- Sichuan University
For direct contact, visit the study record on ClinicalTrials.gov .